RT Journal Article
SR Electronic
T1 Multi-omics approach identifies novel age-, time- and treatment-related immunopathological signatures in MIS-C and pediatric COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.24.21263853
DO 10.1101/2021.09.24.21263853
A1 Keith Sacco
A1 Riccardo Castagnoli
A1 Svetlana Vakkilainen
A1 Can Liu
A1 Ottavia M. Delmonte
A1 Cihan Oguz
A1 Ian M. Kaplan
A1 Sara Alehashemi
A1 Peter D. Burbelo
A1 Farzana Bhuyan
A1 Adriana A. de Jesus
A1 Kerry Dobbs
A1 Lindsey B. Rosen
A1 Aristine Cheng
A1 Elana Shaw
A1 Mikko S. Vakkilainen
A1 Francesca Pala
A1 Justin Lack
A1 Yu Zhang
A1 Danielle L. Fink
A1 Vasileios Oikonomou
A1 Andrew L. Snow
A1 Clifton L. Dalgard
A1 Jinguo Chen
A1 Brian A. Sellers
A1 Gina A. Montealegre Sanchez
A1 Karyl Barron
A1 Emma Rey
A1 Cecilia Vial
A1 Maria Cecilia Poli
A1 Amelia Licari
A1 Daniela Montagna
A1 Gian Luigi Marseglia
A1 Francesco Licciardi
A1 Ugo Ramenghi
A1 Valentina Discepolo
A1 Andrea Lo Vecchio
A1 Alfredo Guarino
A1 Eli M. Eisenstein
A1 Luisa Imberti
A1 Alessandra Sottini
A1 Andrea Biondi
A1 Sayonara Mató
A1 Dana Gerstbacher
A1 Meng Truong
A1 Michael A. Stack
A1 Mary Magliocco
A1 Marita Bosticardo
A1 Tomoki Kawai
A1 Jeffrey J. Danielson
A1 Tyler Hulett
A1 Manor Askenazi
A1 NIAID Immune Response to COVID Group
A1 Chile MIS-C Group
A1 Pavia Pediatric COVID-19 Group
A1 Jeffrey I. Cohen
A1 Helen C. Su
A1 Douglas B. Kuhns
A1 Michail S. Lionakis
A1 Thomas M. Snyder
A1 Steven M. Holland
A1 Raphaela Goldbach-Mansky
A1 John S. Tsang
A1 Luigi D. Notarangelo
A1 Members of the NIAID Immune Response to COVID Group
A1 Jason Barnett
A1 Xi Cheng
A1 Krishnaveni Kaladi
A1 Vasu Kuram
A1 Joseph Mackey
A1 Neha M. Bansal
A1 Andrew J. Martins
A1 Boaz Palterer
A1 Helen Matthews
A1 Uma Mudunuri
A1 Marshall Nambiar
A1 Andrew Oler
A1 Andre Rastegar
A1 Smilee Samuel
A1 Conrad Shyu
A1 Varsha Waingankar
A1 Sarah Weber
A1 Sandhya Xirasagar
A1 Members of the Chile MIS-C Group
A1 Yazmin Espinosa
A1 Camila Astudillo
A1 Members of the Pavia Pediatric COVID-19 Group
A1 Maria De Filippo
A1 Martina Votto
A1 Lorenza Montagna
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.24.21263853.abstract
AB Pediatric COVID-19 (pCOVID-19) is rarely severe, however a minority of SARS-CoV-2-infected children may develop MIS-C, a multisystem inflammatory syndrome with significant morbidity. In this longitudinal multi-institutional study, we used multi-omics to identify novel time- and treatment-related immunopathological signatures in children with COVID-19 (n=105) and MIS-C (n=76). pCOVID-19 was characterized by enhanced type I IFN responses, and MIS-C by type II IFN- and NF-κB dependent responses, matrisome activation, and increased levels of Spike protein. Reduced levels of IL-33 in pCOVID-19, and of CCL22 in MIS-C suggested suppression of Th2 responses. Expansion of TRBV11-2 T-cell clonotypes in MIS-C was associated with inflammation and signatures of T-cell activation, and was reversed by glucocorticoids. The association of MIS-C with the combination of HLA A*02, B*35, C*04 alleles suggests genetic susceptibility. MIS-C B cells showed higher mutation load. Use of IVIG was identified as a confounding factor in the interpretation of autoantibody levels.Competing Interest StatementTH is an employee and shareholder of CDI Laboratories. MA is a consultant for CDI Laboratories and the owner of Biomedical Hosting, LLC. TMS and IMK declare employment and equity ownership with Adaptive Biotechnologies. Funding StatementThis work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases and National Institute of Dental and Craniofacial Research, National Institutes of Health (grant ZIA AI001270-01 to LDN and ZIA AI001265 to HCS), by Regione Lombardia, Italy (project 'Risposta immune in pazienti con COVID-19 e co-morbidita' to RC, AL, DM, GLM for Pavia, Italy and LI and AS for Brescia, Italy), by ANID COVID 0999, Fondecyt no 11181222 (to MCP, Chile). In addition, this project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024 (to DBK). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Moreover, the opinions and assertions expressed herein are those of the authors and are not to be construed as reflecting the views of Uniformed Services University of the Health Sciences or the United States Department of Defense. RC is a participant in the USA National Institutes of Health (NIH) Graduate Partnership Program between NIH and the University of Pavia, Italy. SV is funded by The Finnish Medical Foundation and Orion Research Foundation sr.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Chile IRB: Comite Etico Cientifico Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile Protocol: 2020-41 Title: Infeccion por Sars CoV-2 y enfermedad Covid-19: caracterizacion epidemiologica, clinica, virologica e inmunologica (SARS-CoV-2 infection and COVID-19: Epidemiologic, clinical, virologic and immunologic characterization) Pavia, Italy IRB: Ethics Committee of the Fondazione IRCCS Policlinico San Matteo, Pavia Protocol: 20200037677 Title: Analisi comprensiva della risposta immunitaria innata ed adattativa durante la fase acuta e la convalescenza in COVID-19 Turin, Italy IRB: Comitato Etico Interaziendale A.O.U. Citta della Salute e della Scienza di Torino Protocol: 00282/2020 Title: Immunofenotipo SCiKH Naples, Italy IRB: Ethics Committee of the University of Naples Federico II Protocol: 158/20 for all COVID-19 patients Title: Analisi comprensiva della risposta immunitaria innata ed adattativa durante la fase acuta e la convalescenza dell infezione da COVID-19 (Comprehensive analysis of the innate and adaptive immune response in acute phase and convalescence of COVID-19 patients) Brescia, Italy IRB: Comitato Etico Provinciale Protocol: NP-4000 Title: Indagini di laboratorio e infezione da COVID19, Studio CORONAlab Monza, Italy IRB: University of Milano Bicocca, San Gerardo Hospital, Monza and Ethics Committee of the National Institute of Infectious Diseases 'Lazzaro Spallanzani' Protocol: 84/2020 Title: Observational cohort study on the natural history of hospitalized SARS-COV-2 patients: the STORM trial. Israel IRB: Hadassah Medical Organization Institutional Review Board (IRB) for studies involving human subjects. Protocol: HMO-235-20 Title: Collection of blood specimens from patients diagnosed with COVID19, SARS-COV-2 carriers and members of their families, for purposes of monitoring biomarkers and their immune response. IRB NIAID-NIH Protocol: 18-I-0041 (NCT03394053) Title: Investigating the Mechanistic Biology of Primary Immunodeficiency Disorders IRB NIAID-NIH Protocol: 18-I-0128 (NCT 03610802) Title: Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis manuscript will be submitted for peer-review and metadata will be included in this submission.